Trials Begin for Omicron-Specific Coronavirus Vaccine

BioNTech, which changed the course of the epidemic by developing the mRNA-based coronavirus vaccine, and Pfizer, especially omicron variant announced that the new vaccine, which is effective for Pfizer manager Kathrin Jansen In a statement made by the company, it was stated that it is necessary to stay vigilant against the virus and therefore they want the new vaccine to be ready for use as soon as possible.

Trials of Pfizer and BioNTech’s new vaccine effective against the omicron variant, will be done in three groups. According to the statements made, the first group will consist of people who have never been vaccinated. The second group will include people who have received two doses of the BioNTech vaccine. The third group will consist of people who have been vaccinated three doses so far. experimental study, 1,420 adults will cover.

Can the pandemic end with the new vaccine?

Pfizer and BioNTech did not provide detailed information about the new vaccine. About the results to be achieved nothing is known. However, this vaccine is promising for many scientists. Experts believe that a vaccine that focuses directly on omicron could end the pandemic. But here too unclear there are some situations. Although the dominant variant of recent periods is omicron, different variants such as delta can still be seen.

It should be noted that vaccine studies on the Omicron variant are not limited to Pfizer and BioNTech. such that modern is also developing a new coronavirus vaccine focused on omicron. On the other hand; Johnson & Johnson announced that he will start a new vaccine study if necessary. The coming days seem to be more decisive in terms of the course of the epidemic.